Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Neoadjuvant-Adjuvant Erlotinib Promising in Locally Advanced NSCLC
Key clinical point: Neoadjuvant and adjuvant erlotinib may be superior to chemotherapy in locally advanced, EGFR-mutant non–small cell lung cancer.
Major finding: The objective response rate was 54.1% with neoadjuvant erlotinib versus 34.3% with neoadjuvant gemcitabine/cisplatin (odds ratio, 2.26; P = .092).
Study details: A phase 2 randomized controlled trial among 72 patients with stage IIIA-N2 EGFR-mutant NSCLC (EMERGING trial).
Disclosures: Dr. Zhong disclosed receiving honoraria from AstraZeneca, Eli Lilly, Pfizer, Roche, and Sanofi. The trial was supported by the Chinese Thoracic Oncology Group and Shanghai Roche Pharmaceutical.
Zhong W-Z et al. J Clin Oncol. 2019 June 13. doi: 10.1200/JCO.19.00075.